nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Dexamethasone—psoriatic arthritis	0.0528	0.164	CbGbCtD
Bortezomib—CYP2C19—Prednisone—psoriatic arthritis	0.0409	0.127	CbGbCtD
Bortezomib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0327	0.101	CbGbCtD
Bortezomib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0305	0.0945	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—psoriatic arthritis	0.0256	0.0793	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0248	0.0768	CbGbCtD
Bortezomib—CYP2C9—Dexamethasone—psoriatic arthritis	0.0212	0.0659	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—psoriatic arthritis	0.0212	0.0659	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—psoriatic arthritis	0.021	0.065	CbGbCtD
Bortezomib—CYP3A4—Prednisone—psoriatic arthritis	0.0198	0.0614	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0194	0.0603	CbGbCtD
Bortezomib—CTSG—Metabolism of Angiotensinogen to Angiotensins—ACE—psoriatic arthritis	0.0168	0.0859	CbGpPWpGaD
Bortezomib—CTSG—ACE Inhibitor Pathway—ACE—psoriatic arthritis	0.016	0.0819	CbGpPWpGaD
Bortezomib—CYP3A4—Dexamethasone—psoriatic arthritis	0.0124	0.0383	CbGbCtD
Bortezomib—CTSG—skin of body—psoriatic arthritis	0.00544	0.121	CbGeAlD
Bortezomib—PSMA1—skin of body—psoriatic arthritis	0.00522	0.116	CbGeAlD
Bortezomib—CTSG—Peptide hormone metabolism—ACE—psoriatic arthritis	0.00441	0.0226	CbGpPWpGaD
Bortezomib—CTSG—tendon—psoriatic arthritis	0.00414	0.092	CbGeAlD
Bortezomib—PSMD2—skin of body—psoriatic arthritis	0.00388	0.0863	CbGeAlD
Bortezomib—PSMD1—tendon—psoriatic arthritis	0.00334	0.0742	CbGeAlD
Bortezomib—PSMB1—skin of body—psoriatic arthritis	0.00298	0.0663	CbGeAlD
Bortezomib—PSMA1—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00297	0.0152	CbGpPWpGaD
Bortezomib—PSMD2—tendon—psoriatic arthritis	0.00295	0.0657	CbGeAlD
Bortezomib—PSMD1—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00295	0.0151	CbGpPWpGaD
Bortezomib—PSMD2—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00294	0.015	CbGpPWpGaD
Bortezomib—PSMB8—tendon—psoriatic arthritis	0.00294	0.0653	CbGeAlD
Bortezomib—PSMB2—skin of body—psoriatic arthritis	0.00291	0.0646	CbGeAlD
Bortezomib—PSMA1—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00283	0.0145	CbGpPWpGaD
Bortezomib—PSMD1—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00282	0.0144	CbGpPWpGaD
Bortezomib—PSMD2—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00281	0.0144	CbGpPWpGaD
Bortezomib—PSMA1—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.0028	0.0143	CbGpPWpGaD
Bortezomib—PSMD1—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00278	0.0143	CbGpPWpGaD
Bortezomib—PSMD2—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00277	0.0142	CbGpPWpGaD
Bortezomib—PSMB5—tendon—psoriatic arthritis	0.00259	0.0577	CbGeAlD
Bortezomib—PSMA1—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00231	0.0118	CbGpPWpGaD
Bortezomib—PSMD1—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.0023	0.0118	CbGpPWpGaD
Bortezomib—PSMD2—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00229	0.0117	CbGpPWpGaD
Bortezomib—PSMB1—tendon—psoriatic arthritis	0.00227	0.0504	CbGeAlD
Bortezomib—PSMB2—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00225	0.0115	CbGpPWpGaD
Bortezomib—PSMB5—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00225	0.0115	CbGpPWpGaD
Bortezomib—PSMB1—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00225	0.0115	CbGpPWpGaD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.00222	0.0114	CbGpPWpGaD
Bortezomib—PSMB8—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00222	0.0114	CbGpPWpGaD
Bortezomib—PSMB2—tendon—psoriatic arthritis	0.00221	0.0492	CbGeAlD
Bortezomib—PSMB2—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00215	0.011	CbGpPWpGaD
Bortezomib—PSMB1—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00215	0.011	CbGpPWpGaD
Bortezomib—PSMB5—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00215	0.011	CbGpPWpGaD
Bortezomib—PSMB2—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00212	0.0109	CbGpPWpGaD
Bortezomib—PSMB5—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00212	0.0109	CbGpPWpGaD
Bortezomib—PSMB1—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00212	0.0109	CbGpPWpGaD
Bortezomib—PSMB8—Proteasome Degradation—HLA-C—psoriatic arthritis	0.00212	0.0108	CbGpPWpGaD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.0021	0.0108	CbGpPWpGaD
Bortezomib—PSMB8—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00209	0.0107	CbGpPWpGaD
Bortezomib—PSMB8—Interferon alpha/beta signaling—HLA-C—psoriatic arthritis	0.00204	0.0104	CbGpPWpGaD
Bortezomib—SLC31A1—tendon—psoriatic arthritis	0.00192	0.0426	CbGeAlD
Bortezomib—PSMB1—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00175	0.00897	CbGpPWpGaD
Bortezomib—PSMB5—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00175	0.00897	CbGpPWpGaD
Bortezomib—PSMB2—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00175	0.00897	CbGpPWpGaD
Bortezomib—PSMB8—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00173	0.00885	CbGpPWpGaD
Bortezomib—PSMA1—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00168	0.00859	CbGpPWpGaD
Bortezomib—PSMD1—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00167	0.00854	CbGpPWpGaD
Bortezomib—PSMD2—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00166	0.0085	CbGpPWpGaD
Bortezomib—PSMA1—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00165	0.00848	CbGpPWpGaD
Bortezomib—PSMD1—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00165	0.00844	CbGpPWpGaD
Bortezomib—PSMD2—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00164	0.0084	CbGpPWpGaD
Bortezomib—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.00151	0.00774	CbGpPWpGaD
Bortezomib—PSMA1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00139	0.00714	CbGpPWpGaD
Bortezomib—PSMD1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00139	0.00711	CbGpPWpGaD
Bortezomib—PSMD2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00138	0.00707	CbGpPWpGaD
Bortezomib—PSMA1—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00137	0.007	CbGpPWpGaD
Bortezomib—PSMD1—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00136	0.00697	CbGpPWpGaD
Bortezomib—PSMD2—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00135	0.00694	CbGpPWpGaD
Bortezomib—PSMB2—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00127	0.00651	CbGpPWpGaD
Bortezomib—PSMB5—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00127	0.00651	CbGpPWpGaD
Bortezomib—PSMB1—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00127	0.00651	CbGpPWpGaD
Bortezomib—PSMB5—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00125	0.00642	CbGpPWpGaD
Bortezomib—PSMB1—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00125	0.00642	CbGpPWpGaD
Bortezomib—PSMB2—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00125	0.00642	CbGpPWpGaD
Bortezomib—PSMB8—Proteasome Degradation—HLA-B—psoriatic arthritis	0.00125	0.00641	CbGpPWpGaD
Bortezomib—PSMB8—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00124	0.00633	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—REL—psoriatic arthritis	0.00123	0.00631	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—REL—psoriatic arthritis	0.00123	0.00628	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—REL—psoriatic arthritis	0.00122	0.00625	CbGpPWpGaD
Bortezomib—PSMB8—Interferon alpha/beta signaling—HLA-B—psoriatic arthritis	0.00121	0.00618	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00106	0.00541	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00106	0.00541	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00106	0.00541	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00104	0.00534	CbGpPWpGaD
Bortezomib—PSMB2—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00104	0.00531	CbGpPWpGaD
Bortezomib—PSMB5—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00104	0.00531	CbGpPWpGaD
Bortezomib—PSMB1—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00104	0.00531	CbGpPWpGaD
Bortezomib—PSMB8—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00102	0.00523	CbGpPWpGaD
Bortezomib—PSMB8—Interferon Signaling—HLA-C—psoriatic arthritis	0.000949	0.00486	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—REL—psoriatic arthritis	0.000933	0.00478	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—REL—psoriatic arthritis	0.000933	0.00478	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—REL—psoriatic arthritis	0.000933	0.00478	CbGpPWpGaD
Bortezomib—PSMA1—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.000923	0.00473	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—REL—psoriatic arthritis	0.00092	0.00471	CbGpPWpGaD
Bortezomib—PSMD1—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.000919	0.00471	CbGpPWpGaD
Bortezomib—PSMD2—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.000914	0.00468	CbGpPWpGaD
Bortezomib—CYP1A1—skin of body—psoriatic arthritis	0.000855	0.019	CbGeAlD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000854	0.00438	CbGpPWpGaD
Bortezomib—CTSG—Metabolism of proteins—ACE—psoriatic arthritis	0.000832	0.00426	CbGpPWpGaD
Bortezomib—PTGS1—skin of body—psoriatic arthritis	0.000751	0.0167	CbGeAlD
Bortezomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.000699	0.00358	CbGpPWpGaD
Bortezomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.000699	0.00358	CbGpPWpGaD
Bortezomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.000699	0.00358	CbGpPWpGaD
Bortezomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.00069	0.00353	CbGpPWpGaD
Bortezomib—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000684	0.00351	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000634	0.00325	CbGpPWpGaD
Bortezomib—PSMD2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.000623	0.0483	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Methylprednisolone—psoriatic arthritis	0.00062	0.0481	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000613	0.0476	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000613	0.0476	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000599	0.0465	CbGdCrCtD
Bortezomib—PTGS1—tendon—psoriatic arthritis	0.000572	0.0127	CbGeAlD
Bortezomib—PSMB8—Interferon Signaling—HLA-B—psoriatic arthritis	0.000561	0.00288	CbGpPWpGaD
Bortezomib—PSMB8—Medrysone—Prednisolone—psoriatic arthritis	0.000552	0.0428	CbGdCrCtD
Bortezomib—PSMA1—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000546	0.0028	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000545	0.00279	CbGpPWpGaD
Bortezomib—PSMD1—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000543	0.00278	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—MEFV—psoriatic arthritis	0.000541	0.00277	CbGpPWpGaD
Bortezomib—PSMD2—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000541	0.00277	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—MEFV—psoriatic arthritis	0.000539	0.00276	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—MEFV—psoriatic arthritis	0.000536	0.00275	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—REL—psoriatic arthritis	0.000496	0.00254	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—REL—psoriatic arthritis	0.000494	0.00253	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—REL—psoriatic arthritis	0.000492	0.00252	CbGpPWpGaD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000484	0.00248	CbGpPWpGaD
Bortezomib—PSMB8—Interferon Signaling—HLA-DRB1—psoriatic arthritis	0.000475	0.00243	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000466	0.00239	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000457	0.00234	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000455	0.00233	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000453	0.00232	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Methylprednisolone—psoriatic arthritis	0.000449	0.0348	CbGdCrCtD
Bortezomib—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000444	0.00227	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—psoriatic arthritis	0.000442	0.0342	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—psoriatic arthritis	0.000442	0.0342	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—psoriatic arthritis	0.000432	0.0335	CbGdCrCtD
Bortezomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000414	0.00212	CbGpPWpGaD
Bortezomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000414	0.00212	CbGpPWpGaD
Bortezomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000414	0.00212	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MEFV—psoriatic arthritis	0.00041	0.0021	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MEFV—psoriatic arthritis	0.00041	0.0021	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MEFV—psoriatic arthritis	0.00041	0.0021	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Prednisone—psoriatic arthritis	0.00041	0.0318	CbGdCrCtD
Bortezomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.000408	0.00209	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MEFV—psoriatic arthritis	0.000404	0.00207	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—psoriatic arthritis	0.0004	0.031	CbGdCrCtD
Bortezomib—PSMB2—Adaptive Immune System—REL—psoriatic arthritis	0.000376	0.00193	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—REL—psoriatic arthritis	0.000376	0.00193	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—REL—psoriatic arthritis	0.000376	0.00193	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000375	0.00192	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—REL—psoriatic arthritis	0.000371	0.0019	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000346	0.00177	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000346	0.00177	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000346	0.00177	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Methylprednisolone—psoriatic arthritis	0.000342	0.0265	CbGdCrCtD
Bortezomib—PSMB8—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000341	0.00175	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Betamethasone—psoriatic arthritis	0.000336	0.0261	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—psoriatic arthritis	0.000336	0.0261	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—psoriatic arthritis	0.000329	0.0255	CbGdCrCtD
Bortezomib—PSMA1—Apoptosis—TNF—psoriatic arthritis	0.000322	0.00165	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—TNF—psoriatic arthritis	0.000321	0.00164	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—TNF—psoriatic arthritis	0.000319	0.00163	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000317	0.00163	CbGpPWpGaD
Bortezomib—PSMD2—Betamethasone—Methylprednisolone—psoriatic arthritis	0.000316	0.0245	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.000316	0.0245	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisone—psoriatic arthritis	0.000312	0.0242	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—psoriatic arthritis	0.000311	0.0241	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—psoriatic arthritis	0.000311	0.0241	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—psoriatic arthritis	0.000304	0.0236	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000304	0.0236	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—psoriatic arthritis	0.000304	0.0236	CbGdCrCtD
Bortezomib—PSMA1—Immune System—REL—psoriatic arthritis	0.000301	0.00154	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—REL—psoriatic arthritis	0.0003	0.00154	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—REL—psoriatic arthritis	0.000298	0.00153	CbGpPWpGaD
Bortezomib—PSMD2—Dexamethasone—Prednisone—psoriatic arthritis	0.000288	0.0224	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—psoriatic arthritis	0.000288	0.0224	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—psoriatic arthritis	0.000281	0.0218	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—psoriatic arthritis	0.000281	0.0218	CbGdCrCtD
Bortezomib—PSMA1—Immune System—HLA-C—psoriatic arthritis	0.000277	0.00142	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HLA-C—psoriatic arthritis	0.000276	0.00141	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HLA-C—psoriatic arthritis	0.000274	0.00141	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.00027	0.00138	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000269	0.00138	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000268	0.00137	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TNF—psoriatic arthritis	0.000244	0.00125	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TNF—psoriatic arthritis	0.000244	0.00125	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TNF—psoriatic arthritis	0.000244	0.00125	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TNF—psoriatic arthritis	0.000241	0.00123	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000238	0.00122	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000238	0.00122	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000229	0.00117	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—REL—psoriatic arthritis	0.000228	0.00117	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—REL—psoriatic arthritis	0.000228	0.00117	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—REL—psoriatic arthritis	0.000228	0.00117	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000228	0.00117	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000227	0.00116	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—REL—psoriatic arthritis	0.000225	0.00115	CbGpPWpGaD
Bortezomib—Insomnia—Prednisolone—psoriatic arthritis	0.000213	0.000502	CcSEcCtD
Bortezomib—Shock—Methylprednisolone—psoriatic arthritis	0.000213	0.000501	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000212	0.0005	CcSEcCtD
Bortezomib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000212	0.0005	CcSEcCtD
Bortezomib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000212	0.000499	CcSEcCtD
Bortezomib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000212	0.000499	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—psoriatic arthritis	0.000212	0.000499	CcSEcCtD
Bortezomib—Paraesthesia—Prednisolone—psoriatic arthritis	0.000212	0.000499	CcSEcCtD
Bortezomib—Tachycardia—Triamcinolone—psoriatic arthritis	0.000212	0.000498	CcSEcCtD
Bortezomib—Mental disorder—Prednisone—psoriatic arthritis	0.000211	0.000498	CcSEcCtD
Bortezomib—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000211	0.000497	CcSEcCtD
Bortezomib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00021	0.000495	CcSEcCtD
Bortezomib—Erythema—Prednisone—psoriatic arthritis	0.00021	0.000495	CcSEcCtD
Bortezomib—Malnutrition—Prednisone—psoriatic arthritis	0.00021	0.000495	CcSEcCtD
Bortezomib—PSMB2—Immune System—HLA-C—psoriatic arthritis	0.00021	0.00108	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-C—psoriatic arthritis	0.00021	0.00108	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HLA-C—psoriatic arthritis	0.00021	0.00108	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00021	0.000494	CcSEcCtD
Bortezomib—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000209	0.000493	CcSEcCtD
Bortezomib—Convulsion—Dexamethasone—psoriatic arthritis	0.000209	0.000492	CcSEcCtD
Bortezomib—Convulsion—Betamethasone—psoriatic arthritis	0.000209	0.000492	CcSEcCtD
Bortezomib—Hypertension—Dexamethasone—psoriatic arthritis	0.000208	0.00049	CcSEcCtD
Bortezomib—Hypertension—Betamethasone—psoriatic arthritis	0.000208	0.00049	CcSEcCtD
Bortezomib—PSMB8—Immune System—HLA-C—psoriatic arthritis	0.000207	0.00106	CbGpPWpGaD
Bortezomib—Myalgia—Dexamethasone—psoriatic arthritis	0.000205	0.000483	CcSEcCtD
Bortezomib—Myalgia—Betamethasone—psoriatic arthritis	0.000205	0.000483	CcSEcCtD
Bortezomib—PSMB5—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000205	0.00105	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000205	0.00105	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000205	0.00105	CbGpPWpGaD
Bortezomib—Anxiety—Dexamethasone—psoriatic arthritis	0.000205	0.000482	CcSEcCtD
Bortezomib—Anxiety—Betamethasone—psoriatic arthritis	0.000205	0.000482	CcSEcCtD
Bortezomib—PSMA1—Immune System—NOD2—psoriatic arthritis	0.000204	0.00104	CbGpPWpGaD
Bortezomib—Discomfort—Betamethasone—psoriatic arthritis	0.000203	0.000478	CcSEcCtD
Bortezomib—Discomfort—Dexamethasone—psoriatic arthritis	0.000203	0.000478	CcSEcCtD
Bortezomib—PSMD1—Immune System—NOD2—psoriatic arthritis	0.000203	0.00104	CbGpPWpGaD
Bortezomib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000203	0.000477	CcSEcCtD
Bortezomib—Hypotension—Methylprednisolone—psoriatic arthritis	0.000202	0.000476	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000202	0.00103	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NOD2—psoriatic arthritis	0.000202	0.00103	CbGpPWpGaD
Bortezomib—Pain—Prednisolone—psoriatic arthritis	0.000202	0.000475	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000202	0.000475	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—psoriatic arthritis	0.000202	0.000475	CcSEcCtD
Bortezomib—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	0.000201	0.00103	CbGpPWpGaD
Bortezomib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000199	0.000469	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—psoriatic arthritis	0.000198	0.000466	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000198	0.000465	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000198	0.000465	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000197	0.000464	CcSEcCtD
Bortezomib—Oedema—Betamethasone—psoriatic arthritis	0.000197	0.000463	CcSEcCtD
Bortezomib—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000197	0.000463	CcSEcCtD
Bortezomib—Oedema—Dexamethasone—psoriatic arthritis	0.000197	0.000463	CcSEcCtD
Bortezomib—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000197	0.000463	CcSEcCtD
Bortezomib—Insomnia—Triamcinolone—psoriatic arthritis	0.000196	0.000462	CcSEcCtD
Bortezomib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000196	0.000461	CcSEcCtD
Bortezomib—Infection—Dexamethasone—psoriatic arthritis	0.000196	0.00046	CcSEcCtD
Bortezomib—Infection—Betamethasone—psoriatic arthritis	0.000196	0.00046	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000195	0.000459	CcSEcCtD
Bortezomib—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000195	0.000459	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000194	0.000458	CcSEcCtD
Bortezomib—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000194	0.000458	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—psoriatic arthritis	0.000194	0.000458	CcSEcCtD
Bortezomib—Anaemia—Prednisone—psoriatic arthritis	0.000194	0.000457	CcSEcCtD
Bortezomib—Shock—Dexamethasone—psoriatic arthritis	0.000194	0.000456	CcSEcCtD
Bortezomib—Shock—Betamethasone—psoriatic arthritis	0.000194	0.000456	CcSEcCtD
Bortezomib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000193	0.000455	CcSEcCtD
Bortezomib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000193	0.000454	CcSEcCtD
Bortezomib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000193	0.000454	CcSEcCtD
Bortezomib—Agitation—Prednisone—psoriatic arthritis	0.000193	0.000454	CcSEcCtD
Bortezomib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000193	0.000454	CcSEcCtD
Bortezomib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000193	0.000454	CcSEcCtD
Bortezomib—Tachycardia—Dexamethasone—psoriatic arthritis	0.000192	0.000452	CcSEcCtD
Bortezomib—Tachycardia—Betamethasone—psoriatic arthritis	0.000192	0.000452	CcSEcCtD
Bortezomib—Angioedema—Prednisone—psoriatic arthritis	0.000192	0.000452	CcSEcCtD
Bortezomib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000191	0.00045	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000191	0.000449	CcSEcCtD
Bortezomib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000191	0.000449	CcSEcCtD
Bortezomib—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00019	0.000448	CcSEcCtD
Bortezomib—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00019	0.000448	CcSEcCtD
Bortezomib—Malaise—Prednisone—psoriatic arthritis	0.000189	0.000446	CcSEcCtD
Bortezomib—Vertigo—Prednisone—psoriatic arthritis	0.000189	0.000444	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—psoriatic arthritis	0.000188	0.000444	CcSEcCtD
Bortezomib—Syncope—Prednisone—psoriatic arthritis	0.000188	0.000443	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—psoriatic arthritis	0.000188	0.000443	CcSEcCtD
Bortezomib—Anorexia—Betamethasone—psoriatic arthritis	0.000188	0.000442	CcSEcCtD
Bortezomib—Anorexia—Dexamethasone—psoriatic arthritis	0.000188	0.000442	CcSEcCtD
Bortezomib—Urticaria—Prednisolone—psoriatic arthritis	0.000187	0.000441	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000187	0.000441	CcSEcCtD
Bortezomib—Fatigue—Triamcinolone—psoriatic arthritis	0.000187	0.00044	CcSEcCtD
Bortezomib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000187	0.000439	CcSEcCtD
Bortezomib—Pain—Triamcinolone—psoriatic arthritis	0.000186	0.000437	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—psoriatic arthritis	0.000185	0.000435	CcSEcCtD
Bortezomib—Hypotension—Betamethasone—psoriatic arthritis	0.000184	0.000433	CcSEcCtD
Bortezomib—Hypotension—Dexamethasone—psoriatic arthritis	0.000184	0.000433	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Methylprednisolone—psoriatic arthritis	0.000183	0.0142	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.000183	0.0142	CbGdCrCtD
Bortezomib—Angiopathy—Methotrexate—psoriatic arthritis	0.000183	0.000431	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—psoriatic arthritis	0.000182	0.000429	CcSEcCtD
Bortezomib—Convulsion—Prednisone—psoriatic arthritis	0.000182	0.000428	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000182	0.000428	CcSEcCtD
Bortezomib—Hypertension—Prednisone—psoriatic arthritis	0.000181	0.000427	CcSEcCtD
Bortezomib—Chills—Methotrexate—psoriatic arthritis	0.000181	0.000426	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—psoriatic arthritis	0.00018	0.014	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—psoriatic arthritis	0.00018	0.014	CbGdCrCtD
Bortezomib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000179	0.000422	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000179	0.000422	CcSEcCtD
Bortezomib—Myalgia—Prednisone—psoriatic arthritis	0.000179	0.000421	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—psoriatic arthritis	0.000179	0.000421	CcSEcCtD
Bortezomib—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000179	0.000421	CcSEcCtD
Bortezomib—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000178	0.00042	CcSEcCtD
Bortezomib—Anxiety—Prednisone—psoriatic arthritis	0.000178	0.00042	CcSEcCtD
Bortezomib—Insomnia—Betamethasone—psoriatic arthritis	0.000178	0.000419	CcSEcCtD
Bortezomib—Insomnia—Dexamethasone—psoriatic arthritis	0.000178	0.000419	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000178	0.000418	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000177	0.000417	CcSEcCtD
Bortezomib—Paraesthesia—Betamethasone—psoriatic arthritis	0.000177	0.000416	CcSEcCtD
Bortezomib—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000177	0.000416	CcSEcCtD
Bortezomib—Discomfort—Prednisone—psoriatic arthritis	0.000177	0.000416	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—psoriatic arthritis	0.000177	0.000416	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—psoriatic arthritis	0.000176	0.0137	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000176	0.0137	CbGdCrCtD
Bortezomib—Malnutrition—Methotrexate—psoriatic arthritis	0.000176	0.000413	CcSEcCtD
Bortezomib—Erythema—Methotrexate—psoriatic arthritis	0.000176	0.000413	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000174	0.000409	CcSEcCtD
Bortezomib—PSMB5—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000173	0.000888	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000173	0.000888	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000173	0.000888	CbGpPWpGaD
Bortezomib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000173	0.000408	CcSEcCtD
Bortezomib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000173	0.000408	CcSEcCtD
Bortezomib—Urticaria—Triamcinolone—psoriatic arthritis	0.000172	0.000406	CcSEcCtD
Bortezomib—Urticaria—Methylprednisolone—psoriatic arthritis	0.000172	0.000405	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000172	0.000405	CcSEcCtD
Bortezomib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000171	0.000404	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000171	0.000404	CcSEcCtD
Bortezomib—Oedema—Prednisone—psoriatic arthritis	0.000171	0.000404	CcSEcCtD
Bortezomib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000171	0.000403	CcSEcCtD
Bortezomib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000171	0.000403	CcSEcCtD
Bortezomib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000171	0.000403	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000171	0.000875	CbGpPWpGaD
Bortezomib—Infection—Prednisone—psoriatic arthritis	0.00017	0.000401	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00017	0.0004	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00017	0.0004	CcSEcCtD
Bortezomib—Back pain—Methotrexate—psoriatic arthritis	0.00017	0.0004	CcSEcCtD
Bortezomib—Fatigue—Dexamethasone—psoriatic arthritis	0.00017	0.0004	CcSEcCtD
Bortezomib—Fatigue—Betamethasone—psoriatic arthritis	0.00017	0.0004	CcSEcCtD
Bortezomib—Shock—Prednisone—psoriatic arthritis	0.000169	0.000397	CcSEcCtD
Bortezomib—Pain—Betamethasone—psoriatic arthritis	0.000168	0.000396	CcSEcCtD
Bortezomib—Pain—Dexamethasone—psoriatic arthritis	0.000168	0.000396	CcSEcCtD
Bortezomib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000168	0.000396	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—psoriatic arthritis	0.000167	0.000394	CcSEcCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—psoriatic arthritis	0.000167	0.013	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—psoriatic arthritis	0.000167	0.013	CbGdCrCtD
Bortezomib—Skin disorder—Prednisone—psoriatic arthritis	0.000167	0.000392	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000166	0.00039	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—psoriatic arthritis	0.000165	0.000389	CcSEcCtD
Bortezomib—PSMA1—Immune System—HLA-B—psoriatic arthritis	0.000164	0.000839	CbGpPWpGaD
Bortezomib—Anorexia—Prednisone—psoriatic arthritis	0.000163	0.000385	CcSEcCtD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—psoriatic arthritis	0.000163	0.0127	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—psoriatic arthritis	0.000163	0.0127	CbGdCrCtD
Bortezomib—PSMD1—Immune System—HLA-B—psoriatic arthritis	0.000163	0.000835	CbGpPWpGaD
Bortezomib—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000163	0.000383	CcSEcCtD
Bortezomib—PSMD2—Immune System—HLA-B—psoriatic arthritis	0.000162	0.000831	CbGpPWpGaD
Bortezomib—Anaemia—Methotrexate—psoriatic arthritis	0.000162	0.000382	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000162	0.000382	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000162	0.000382	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000161	0.000379	CcSEcCtD
Bortezomib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000161	0.000379	CcSEcCtD
Bortezomib—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00016	0.000376	CcSEcCtD
Bortezomib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000159	0.000375	CcSEcCtD
Bortezomib—Malaise—Methotrexate—psoriatic arthritis	0.000158	0.000373	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—psoriatic arthritis	0.000158	0.000371	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—psoriatic arthritis	0.000157	0.00037	CcSEcCtD
Bortezomib—Urticaria—Betamethasone—psoriatic arthritis	0.000156	0.000368	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—psoriatic arthritis	0.000156	0.000368	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000156	0.000368	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—psoriatic arthritis	0.000156	0.000367	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—psoriatic arthritis	0.000156	0.000366	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000156	0.000366	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000156	0.000366	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000156	0.000366	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000156	0.000366	CcSEcCtD
Bortezomib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000155	0.000366	CcSEcCtD
Bortezomib—Insomnia—Prednisone—psoriatic arthritis	0.000155	0.000365	CcSEcCtD
Bortezomib—PSMB1—Immune System—NOD2—psoriatic arthritis	0.000154	0.000791	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NOD2—psoriatic arthritis	0.000154	0.000791	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NOD2—psoriatic arthritis	0.000154	0.000791	CbGpPWpGaD
Bortezomib—Paraesthesia—Prednisone—psoriatic arthritis	0.000154	0.000362	CcSEcCtD
Bortezomib—Pruritus—Triamcinolone—psoriatic arthritis	0.000153	0.000361	CcSEcCtD
Bortezomib—Cough—Methotrexate—psoriatic arthritis	0.000153	0.000361	CcSEcCtD
Bortezomib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000153	0.000361	CcSEcCtD
Bortezomib—PSMB8—Immune System—NOD2—psoriatic arthritis	0.000152	0.00078	CbGpPWpGaD
Bortezomib—Convulsion—Methotrexate—psoriatic arthritis	0.000152	0.000358	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000152	0.000776	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000152	0.000776	CbGpPWpGaD
Bortezomib—Dyspepsia—Prednisone—psoriatic arthritis	0.000151	0.000355	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—psoriatic arthritis	0.000149	0.000352	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—psoriatic arthritis	0.000149	0.000352	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—psoriatic arthritis	0.000149	0.000352	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—psoriatic arthritis	0.000149	0.000351	CcSEcCtD
Bortezomib—Rash—Prednisolone—psoriatic arthritis	0.000149	0.00035	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—psoriatic arthritis	0.000149	0.00035	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000148	0.000349	CcSEcCtD
Bortezomib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000148	0.000349	CcSEcCtD
Bortezomib—Fatigue—Prednisone—psoriatic arthritis	0.000148	0.000348	CcSEcCtD
Bortezomib—Headache—Prednisolone—psoriatic arthritis	0.000148	0.000348	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—psoriatic arthritis	0.000148	0.000348	CcSEcCtD
Bortezomib—Constipation—Prednisone—psoriatic arthritis	0.000147	0.000345	CcSEcCtD
Bortezomib—PSMA1—Immune System—CRP—psoriatic arthritis	0.000145	0.000742	CbGpPWpGaD
Bortezomib—Confusional state—Methotrexate—psoriatic arthritis	0.000144	0.00034	CcSEcCtD
Bortezomib—PSMD1—Immune System—CRP—psoriatic arthritis	0.000144	0.000738	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CRP—psoriatic arthritis	0.000143	0.000735	CbGpPWpGaD
Bortezomib—Dizziness—Triamcinolone—psoriatic arthritis	0.000143	0.000338	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000143	0.000337	CcSEcCtD
Bortezomib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000143	0.000337	CcSEcCtD
Bortezomib—Infection—Methotrexate—psoriatic arthritis	0.000142	0.000335	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—psoriatic arthritis	0.000141	0.000333	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—psoriatic arthritis	0.000141	0.000333	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—psoriatic arthritis	0.000141	0.000333	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00014	0.000331	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.00014	0.00033	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00014	0.00033	CcSEcCtD
Bortezomib—Nausea—Prednisolone—psoriatic arthritis	0.00014	0.00033	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—psoriatic arthritis	0.000139	0.000328	CcSEcCtD
Bortezomib—Pruritus—Betamethasone—psoriatic arthritis	0.000139	0.000328	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—psoriatic arthritis	0.000139	0.000328	CcSEcCtD
Bortezomib—PSMA1—Immune System—HLA-DRB1—psoriatic arthritis	0.000139	0.000711	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000138	0.000326	CcSEcCtD
Bortezomib—PSMD1—Immune System—HLA-DRB1—psoriatic arthritis	0.000138	0.000707	CbGpPWpGaD
Bortezomib—Vomiting—Triamcinolone—psoriatic arthritis	0.000138	0.000325	CcSEcCtD
Bortezomib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000138	0.000324	CcSEcCtD
Bortezomib—PSMD2—Immune System—HLA-DRB1—psoriatic arthritis	0.000137	0.000704	CbGpPWpGaD
Bortezomib—Rash—Triamcinolone—psoriatic arthritis	0.000137	0.000322	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000137	0.000322	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—psoriatic arthritis	0.000137	0.000322	CcSEcCtD
Bortezomib—Rash—Methylprednisolone—psoriatic arthritis	0.000136	0.000321	CcSEcCtD
Bortezomib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000136	0.000321	CcSEcCtD
Bortezomib—Urticaria—Prednisone—psoriatic arthritis	0.000136	0.000321	CcSEcCtD
Bortezomib—Headache—Triamcinolone—psoriatic arthritis	0.000136	0.00032	CcSEcCtD
Bortezomib—Headache—Methylprednisolone—psoriatic arthritis	0.000136	0.000319	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—psoriatic arthritis	0.000136	0.000319	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—psoriatic arthritis	0.000136	0.000319	CcSEcCtD
Bortezomib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000135	0.000317	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000135	0.000317	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—psoriatic arthritis	0.000134	0.000315	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000131	0.000307	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—psoriatic arthritis	0.00013	0.000306	CcSEcCtD
Bortezomib—Dizziness—Dexamethasone—psoriatic arthritis	0.00013	0.000306	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—psoriatic arthritis	0.00013	0.000305	CcSEcCtD
Bortezomib—Nausea—Triamcinolone—psoriatic arthritis	0.000129	0.000303	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—psoriatic arthritis	0.000129	0.000303	CcSEcCtD
Bortezomib—Nausea—Methylprednisolone—psoriatic arthritis	0.000129	0.000303	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000128	0.000301	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisone—psoriatic arthritis	0.000126	0.000297	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000126	0.000297	CcSEcCtD
Bortezomib—Vomiting—Betamethasone—psoriatic arthritis	0.000125	0.000295	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—psoriatic arthritis	0.000125	0.000295	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000125	0.000293	CcSEcCtD
Bortezomib—PSMB5—Immune System—HLA-B—psoriatic arthritis	0.000124	0.000636	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-B—psoriatic arthritis	0.000124	0.000636	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-B—psoriatic arthritis	0.000124	0.000636	CbGpPWpGaD
Bortezomib—Rash—Dexamethasone—psoriatic arthritis	0.000124	0.000292	CcSEcCtD
Bortezomib—Rash—Betamethasone—psoriatic arthritis	0.000124	0.000292	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000124	0.000292	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—psoriatic arthritis	0.000124	0.000292	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000124	0.000291	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—psoriatic arthritis	0.000124	0.000291	CcSEcCtD
Bortezomib—Headache—Dexamethasone—psoriatic arthritis	0.000123	0.00029	CcSEcCtD
Bortezomib—Headache—Betamethasone—psoriatic arthritis	0.000123	0.00029	CcSEcCtD
Bortezomib—Asthenia—Prednisone—psoriatic arthritis	0.000123	0.00029	CcSEcCtD
Bortezomib—Pain—Methotrexate—psoriatic arthritis	0.000123	0.000288	CcSEcCtD
Bortezomib—PSMB8—Immune System—HLA-B—psoriatic arthritis	0.000122	0.000627	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NOS2—psoriatic arthritis	0.000122	0.000625	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NOS2—psoriatic arthritis	0.000121	0.000622	CbGpPWpGaD
Bortezomib—Pruritus—Prednisone—psoriatic arthritis	0.000121	0.000286	CcSEcCtD
Bortezomib—PSMD2—Disease—NOS2—psoriatic arthritis	0.000121	0.000619	CbGpPWpGaD
Bortezomib—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000118	0.000278	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—psoriatic arthritis	0.000117	0.000276	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000117	0.000276	CcSEcCtD
Bortezomib—Nausea—Betamethasone—psoriatic arthritis	0.000117	0.000275	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—psoriatic arthritis	0.000117	0.000275	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—psoriatic arthritis	0.000114	0.000268	CcSEcCtD
Bortezomib—Dizziness—Prednisone—psoriatic arthritis	0.000113	0.000267	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000113	0.000267	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000113	0.000267	CcSEcCtD
Bortezomib—PSMB1—Immune System—CRP—psoriatic arthritis	0.00011	0.000562	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CRP—psoriatic arthritis	0.00011	0.000562	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CRP—psoriatic arthritis	0.00011	0.000562	CbGpPWpGaD
Bortezomib—Vomiting—Prednisone—psoriatic arthritis	0.000109	0.000257	CcSEcCtD
Bortezomib—PSMB8—Immune System—CRP—psoriatic arthritis	0.000108	0.000554	CbGpPWpGaD
Bortezomib—Rash—Prednisone—psoriatic arthritis	0.000108	0.000254	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—psoriatic arthritis	0.000108	0.000254	CcSEcCtD
Bortezomib—Headache—Prednisone—psoriatic arthritis	0.000107	0.000253	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000106	0.000249	CcSEcCtD
Bortezomib—PSMB5—Immune System—HLA-DRB1—psoriatic arthritis	0.000105	0.000539	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-DRB1—psoriatic arthritis	0.000105	0.000539	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-DRB1—psoriatic arthritis	0.000105	0.000539	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HLA-DRB1—psoriatic arthritis	0.000104	0.000531	CbGpPWpGaD
Bortezomib—Asthenia—Methotrexate—psoriatic arthritis	0.000103	0.000242	CcSEcCtD
Bortezomib—Nausea—Prednisone—psoriatic arthritis	0.000102	0.00024	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—psoriatic arthritis	0.000101	0.000239	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—psoriatic arthritis	9.8e-05	0.000231	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—psoriatic arthritis	9.47e-05	0.000223	CcSEcCtD
Bortezomib—PSMB2—Disease—NOS2—psoriatic arthritis	9.24e-05	0.000473	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NOS2—psoriatic arthritis	9.24e-05	0.000473	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NOS2—psoriatic arthritis	9.24e-05	0.000473	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NOS2—psoriatic arthritis	9.11e-05	0.000467	CbGpPWpGaD
Bortezomib—Vomiting—Methotrexate—psoriatic arthritis	9.11e-05	0.000214	CcSEcCtD
Bortezomib—Rash—Methotrexate—psoriatic arthritis	9.03e-05	0.000213	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—psoriatic arthritis	9.02e-05	0.000212	CcSEcCtD
Bortezomib—Headache—Methotrexate—psoriatic arthritis	8.97e-05	0.000211	CcSEcCtD
Bortezomib—Nausea—Methotrexate—psoriatic arthritis	8.51e-05	0.0002	CcSEcCtD
